SSR 97225
Alternative Names: SSR97225Latest Information Update: 16 Jul 2016
At a glance
- Originator sanofi-aventis
- Developer Sanofi
- Class Antineoplastics
- Mechanism of Action Mitosis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)